Acute Coronary Syndrome

Clinical Trial Finder

Many patients with acute coronary syndrome are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Comparaison of 2 SpO2 Level Measured by Pulse Oxymetry in Complications of Acute Coronary Syndrome.

Condition:   Infarction, Myocardial
Intervention:   Device: oxygen administration
Sponsor:   Laval University
Completed - verified April 2017

Real-world Use and Prognosis of Beta Blocker in Patients With Acute Coronary Syndrome in the Central China

Condition:   Acute Coronary Syndrome
Sponsor:   Henan Institute of Cardiovascular Epidemiology
Recruiting - verified April 2017

Improving the Referral of Patients With Chest Pain

Conditions:   Acute Coronary Syndrome;   Myocardial Infarction;   Chest Pain
Intervention:   Diagnostic Test: General Practitioner diagnosis with Heart score
Sponsor:   VieCuri Medical Centre
Not yet recruiting - verified April 2017

Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients

Condition:   Non-ST Elevation Myocardial Infarction
Intervention:   Drug: Tirofiban
Sponsor:   Seoul National University Bundang Hospital
Completed - verified April 2017

Bioresorbable Polymer-Coated EES in Patients at High Bleeding Risk Undergoing PCI Followed by 1-Month DAPT

Conditions:   Coronary Artery Disease;   Acute Coronary Syndrome
Interventions:   Drug: Aspirin;   Drug: P2Y12 inhibitor
Sponsor:   Humanitas Hospital, Italy
Not yet recruiting - verified April 2017

Polyprenols (Ropren) in Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Ropren;   Other: Oil
Sponsor:   Tomsk National Research Medical Center of the Russian Academy of Sciences
Enrolling by invitation - verified April 2017

Positive Psychology for Acute Coronary Syndrome Patients

Condition:   ACS - Acute Coronary Syndrome
Interventions:   Behavioral: Positive Psychology + Goal Setting;   Behavioral: Health Behavior Education
Sponsor:   Massachusetts General Hospital
Not yet recruiting - verified April 2017

Safety of Accelerated Rule-out Protocols in Patients Admitted With Chest Pain to a Crowded Chest Pain Unit (CPU)

Conditions:   Acute Coronary Syndrome;   NSTEMI - Non-ST Segment Elevation MI
Intervention:   Diagnostic Test: NSTEMI Rule-Out according to hs-TnT
Sponsor:   University Hospital Heidelberg
Not yet recruiting - verified April 2017

Pragmatic Collaborative Care for Cardiac Inpatients With Depression or Anxiety

Conditions:   Acute Coronary Syndrome;   Heart Failure;   Depression;   Generalized Anxiety Disorder;   Panic Disorder
Intervention:   Behavioral: Collaborative Care
Sponsors:   Massachusetts General Hospital;   National Institutes of Health (NIH)
Not yet recruiting - verified April 2017

Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes

Condition:   Ischemic Heart Disease
Interventions:   Drug: Proleukin;   Drug: Placebo Injection
Sponsors:   Cambridge University Hospitals NHS Foundation Trust;   University of Cambridge
Not yet recruiting - verified April 2017

Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry

Conditions:   Stable Angina;   Unstable Angina;   ACS - Acute Coronary Syndrome;   STEMI;   NSTEMI - Non-ST Segment Elevation MI;   Myocardial Infarction
Intervention:   Device: COBRA PzF Coronary Stent System
Sponsors:   CeloNova BioSciences, Inc.;   Alpin ARC
Active, not recruiting - verified April 2017

Lidocaine 5% Patch (Lidoderm) for the Perioperative Prevention of Acute and Chronic Chest Pain Following Robotic Valve Surgery

Condition:   Perioperative Chest Pain
Interventions:   Drug: Lidoderm 5 % Topical Patch;   Drug: Placebo patch
Sponsors:   The Cleveland Clinic;   Endo Pharmaceuticals
Completed - verified April 2017

Epicardial Ablation in Brugada Syndrome. An Extension Study of 200 BrS.Patients

Condition:   ECG Brugada Pattern
Intervention:   Procedure: Ablation
Sponsor:   IRCCS Policlinico S. Donato
Recruiting - verified April 2017

Familial Investigations of Childhood Cancer Predisposition

Conditions:   Acute Leukemia;   Adenomatous Polyposis;   Adrenocortical Carcinoma;   AML;   BAP1 Tumor Predisposition Syndrome;   Carney Complex;   Choroid Plexus Carcinoma;   Constitutional Mismatch Repair Deficiency Syndrome;   Diamond-Blackfan Anemia;   DICER1 Syndrome;   Dyskeratosis Congenita;   Emberger Syndrome;   Familial Acute Myeloid Leukaemia;   Familial Adenomatous Polyposis;   Fanconi Anemia;   Familial Cancer;   Familial Wilms Tumor;   Familial Neuroblastoma;   GIST;   Hereditary Breast and Ovarian Cancer;   Hereditary Paraganglioma-Pheochromocytoma Syndrome;   Hodgkin Lymphoma;   Juvenile Polyposis;   Li-Fraumeni Syndrome;   Lynch Syndrome;   MDS;   Melanoma Syndrome;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Neuroblastoma;   Neurofibromatosis Type 1;   Neurofibromatosis Type II;   Nevoid Basal Cell Carcinoma Syndrome;   Non Hodgkin Lymphoma;   Noonan Syndrome and Other Rasopathy;   Overgrowth Syndromes;   Pancreatic Cancer;   Peutz-Jeghers Syndrome;   Pheochromocytoma/Paraganglioma;   PTEN Hamartoma Tumor Syndrome;   Retinoblastoma;   Rhabdoid Tumor Predisposition Syndrome;   Rhabdomyosarcoma;   Rothmund-Thomson Syndrome;   Tuberous Sclerosis;   Von Hippel-Lindau Disease
Sponsor:   St. Jude Children's Research Hospital
Recruiting - verified February 2017

The Impact of Early Surgery and Maintenance of Antiplatelet Therapy on Intraoperative Bleeding and Major Adverse Cardiovascular Event After Percutaneous Coronary Intervention

Conditions:   Acute Coronary Syndrome;   Drug-eluting Stent;   Aspirin
Intervention:   Procedure: Non-cardiac surgery
Sponsor:   Seoul National University Hospital
Recruiting - verified April 2017

Transfusion Using Stored Fresh Whole Blood

Conditions:   Trauma;   Hemorrhage;   Coagulopathy
Sponsor:   University of California, Los Angeles
Not yet recruiting - verified April 2017

The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III

Conditions:   Cardiac Arrest;   Renal Failure;   Respiration Failure;   Myocardial Infarction;   Severe Sepsis
Intervention:   Device: Automatic RR Measurement
Sponsor:   Philips Healthcare
Completed - verified April 2017

A Study Evaluating Venetoclax in Combination With Azacitidine Compared With Azacitidine Alone in Participants With Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS)

Condition:   Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
Interventions:   Drug: Venetoclax;   Drug: Azacitidine
Sponsors:   AbbVie;   Genentech, Inc.
Recruiting - verified April 2017

L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects

Condition:   Acute Lung Injury
Interventions:   Drug: L-citrulline;   Other: Placebo
Sponsor:   Asklepion Pharmaceuticals, LLC
Recruiting - verified September 2016

Role of Podocan and Wnt Pathway Regulatory Molecules in Coronary Artery Disease

Condition:   Coronary Artery Disease
Sponsors:   Bassett Healthcare;   Baylor University
Recruiting - verified April 2017

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Conditions:   B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions:   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified December 2016

Clinical Performance Evaluation of AQT90 FLEX TnI and TnT

Condition:   Myocardial Infarction
Sponsor:   Radiometer Medical ApS
Active, not recruiting - verified April 2017

"Me and My Heart" Study

Condition:   Acute Coronary Syndrome
Interventions:   Device: Active group with MEMS;   Device: Active group without MEMS;   Device: Control group with MEMS;   Device: Control group without MEMS
Sponsor:   AstraZeneca
Recruiting - verified April 2017

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

Condition:   Venous Thromboembolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified April 2017

Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting

Conditions:   Coronary Artery Disease;   Myocardial Ischemia;   Myocardial Infarction;   Stent Thrombosis;   Cardiovascular Diseases
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Action Research Group
Recruiting - verified April 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified April 2017

IMproving reModeling in Acute myoCardial Infarction Using Live and Asynchronous TElemedicine.

Conditions:   Left Ventricular Remodeling;   Medication Adherence;   Acute Coronary Syndrome
Intervention:   Other: Telemedicine
Sponsors:   National University Heart Centre, Singapore;   National University, Singapore;   National University Hospital, Singapore;   Tan Tock Seng Hospital
Recruiting - verified September 2016

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Recruiting - verified April 2017

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Condition:   Cost Sharing, Acute Coronary Syndrome
Intervention:   Other: Study voucher card
Sponsors:   AstraZeneca;   Duke Clinical Research Institute
Active, not recruiting - verified April 2017

Saxagliptin and Acute Myocardial Infarction:Effects on Platelet Function

Condition:   Platelet Aggregation During Acute Myocardial Infarction
Interventions:   Drug: saxagliptin;   Drug: placebo
Sponsors:   University of Sao Paulo General Hospital;   InCor Heart Institute
Recruiting - verified January 2017

PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)

Conditions:   Neurofibroma, Plexiform;   Precursor Cell Lymphoblastic Leukemia-Lymphoma;   Leukemia, Prolymphocytic, Acute;   Sarcoma
Intervention:   Drug: PLX3397
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified March 3, 2017

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Acute Leukemia;   Multiple Myeloma
Interventions:   Biological: Rituximab;   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Procedure: Hematopoietic Stem Cell Transplant;   Drug: Palifermin
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified December 9, 2016

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified April 2017

Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide

Condition:   Chronic Granulomatous Disease
Interventions:   Drug: Pre-Transplant Conditioning Medications;   Other: Haploidentical Cellular Infusion;   Drug: Post-Trasnplant Medications;   Radiation: Total Body Irradiation
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Suspended - verified April 7, 2017

Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease

Condition:   Sickle Cell Disease
Intervention:   Drug: Hydroxyurea
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Enrolling by invitation - verified January 31, 2017

Thrombolysis in Ischemic Spinal Cord Stroke

Conditions:   Motor Weakness in Two or Four Limbs;   Damage in the Anterior Spinal Artery (ASA);   Temperature and Superficial Sensation;   Urinary Retention or Bowel Disorder
Intervention:   Drug: Intravenuse Alteplase
Sponsor:   Rabin Medical Center
Active, not recruiting - verified April 2017

Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections

Conditions:   Chronic Lymphocytic Leukemia;   CML (Chronic Myelogenous Leukemia);   MDS (Myelodysplastic Syndrome);   Acute Lymphoblastic Leukemia;   AML (Acute Myelogenous Leukemia)
Interventions:   Biological: MVST;   Biological: MVSTr
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 15, 2017

Prognostic Value of Biomarkers Associated With Endothelial Progenitor Cells Mobilization in Acute Coronary Syndromes

Condition:   Acute Coronary Syndromes
Intervention:   Other: blood sample
Sponsor:   Assistance Publique Hopitaux De Marseille
Active, not recruiting - verified April 2017

The Relationship of Platelet Micro-RNA Expression and Platelet Reactivity in Patients Under Clopidogrel or Ticagrelor Treatment

Conditions:   PRU;   miRNA
Sponsor:   Taipei City Hospital
Recruiting - verified April 2017

Very Early veRsus Deferred Invasive Evaluation Using Computerized Tomography in Patients With Acute Coronary Syndromes

Condition:   Coronary Artery Disease
Interventions:   Procedure: Invasive coronary evaluation (Deferred);   Procedure: Invasive coronary evaluation (Acute)
Sponsors:   Rigshospitalet, Denmark;   University Hospital, Gentofte, Copenhagen
Active, not recruiting - verified April 2017

Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury

Conditions:   Acute Lung Injury;   Sepsis
Interventions:   Drug: Ascorbic Acid;   Drug: Placebo: 5% Dextrose in water
Sponsors:   Virginia Commonwealth University;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2017

CArdiac cT in the Treatment of Acute CHest Pain 2 - Myocardial CT Perfusion

Condition:   Coronary Artery Disease
Interventions:   Procedure: CTA+CTP guided treatment strategy;   Procedure: CTA guided treatment strategy
Sponsors:   Rigshospitalet, Denmark;   Copenhagen University Hospital, Hvidovre;   Amager Hospital;   Bispebjerg Hospital;   Herlev Hospital;   Glostrup University Hospital, Copenhagen;   University Hospital, Gentofte, Copenhagen
Active, not recruiting - verified April 2017

Essential Hypotension and Allostasis Registry

Conditions:   Blood Pressure;   Depression;   Panic Attack;   Fibromyalgia;   POTS;   Inappropriate Sinus Tachycardia;   Coronary Heart Disease;   Acute Coronary Syndrome (ACS);   Acute Myocardial Infarction (AMI);   Cerebrovascular Disease (CVD);   Transient Ischemic Attack (TIA);   Atrial Fibrillation;   Diabetes Mellitus;   Cancer;   Systolic Heart Failure;   Diastolic Heart Failure;   Chronic Fatigue Syndrome;   Syncope;   Vasovagal Syncope
Sponsor:   CES University
Recruiting - verified April 2017

APRV/BIPAP With Spontaneous Breathing on Lung Protection

Conditions:   Respiratory Insufficiency;   Ventilator-Induced Lung Injury
Intervention:   Other: Pressure targeted modes
Sponsors:   St. Michael's Hospital, Toronto;   University of Toronto
Completed - verified April 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified April 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified April 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified April 2017

Age of Blood in Children in Pediatric Intensive Care Units

Condition:   Anemia
Intervention:   Biological: Short storage RBC age
Sponsors:   Washington University School of Medicine;   National Heart, Lung, and Blood Institute (NHLBI);   Canadian Institutes of Health Research (CIHR);   Ministere de la Sante et des Services Sociaux
Recruiting - verified April 2017

Incremental Value of Point of Care H-FABP Testing in Primary Care Patients Suspected of Acute Coronary Syndrome

Conditions:   Acute Coronary Syndrome;   Angina Pectoris, Unstable;   Angina Pectoris, Stable;   Thoracic Diseases
Intervention:   Device: heart type fatty acid binding protein testing
Sponsors:   Maastricht University Medical Center;   FABPulous B.V.
Completed - verified April 2017

Preventing Stem Cell Transplant Complications With a Blood Separator Machine

Conditions:   MDS (Myelodysplastic Syndrome);   Myeloproliferative Disorder;   Lymphoma, Non-Hodgkin;   ALL (Acute B-Lymphoblastic Leukemia);   AML (Acute Meylogenous Leukemia
Intervention:   Device: Graft Manipulation (CD34+ Selection)
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Children's Research Institute
Recruiting - verified April 6, 2017

RITHM - Resonance Imaging Trial for Heart Biomarkers in Adolescent/Young (AYA) Cancer Survivors

Conditions:   if Aortic Stiffness;   Myocardial Wall Strain
Sponsor:   Wake Forest University Health Sciences
Completed - verified April 2017

Low Risk Acute Coronary Syndrome

Condition:   Low Risk Acute Coronary Syndrome
Interventions:   Procedure: Stress Test;   Procedure: No Stress Test
Sponsors:   University of Oklahoma;   VA Office of Research and Development
Completed - verified April 2017

Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant

Conditions:   Acute Myeloid Leukemia;   Acute Lymphoid Leukemia;   Hematopoetic Myelodysplasia;   Leukemia, Myelogenous, Chronic;   Lymphoma, Non-Hodgkin
Intervention:   Drug: Sitagliptin
Sponsors:   Sherif S. Farag;   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting - verified April 2017

Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

Conditions:   Acute Biphenotypic Leukemia;   Acute Erythroid Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Megakaryoblastic Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Mixed Phenotype Acute Leukemia;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Pancytopenia;   Refractory Anemia;   Secondary Acute Myeloid Leukemia
Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Procedure: Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Drug: Thiotepa;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2017

EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures

Condition:   Acute Respiratory Distress Syndrome
Interventions:   Other: Esophageal-pressure guided mechanical ventilation;   Other: High PEEP mechanical ventilation
Sponsors:   Beth Israel Deaconess Medical Center;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2017

Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

Conditions:   Myeldysplastic Syndrome (MDS);   Chronic Myelomonocytic Leukemia;   Bone Marrow Diseases;   Neutropenia;   Acute Myeloid Leukemia (AML)
Interventions:   Drug: Clofarabine;   Drug: Lenalidomide
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Celgene Corporation
Completed - verified February 13, 2017

Transplants With Unlicensed Preserved Cord Blood

Conditions:   Myelodysplastic Syndrome (MDS);   Hematologic Neoplasms;   Hematologic Diseases;   Severe Aplastic Anemia
Intervention:   Procedure: Cord Blood Transplant
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 6, 2016

Improving Blood Stem Cell Collection and Transplant Procedures

Conditions:   Myelodysplastic Syndrome (MDS);   Chronic Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   CML (Chronic Myelogenous Leukemia;   CLL (Chronic Lymphocytic Leukemia)
Intervention:   Procedure: Stem Cell Transplantation
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified March 29, 2017

Assessment of Distal Protection Device in Patients at High Risk for Distal Embolism in Acute Coronary Syndrome (ACS)

Condition:   Coronary Artery Disease
Interventions:   Procedure: Filtrap™ + Thrombus aspiration catheter;   Procedure: Thrombus aspiration catheter
Sponsors:   Yokohama City University Medical Center;   Teikyo University
Completed - verified April 2017

ASP (PPI_H2RA) Study-H2RA Versus PPI for the Prevention of Recurrent UGIB in High-risk Users of Low-dose ASA

Condition:   Upper Gastrointestinal Bleeding
Interventions:   Drug: Rabeprazole;   Drug: Famotidine
Sponsor:   Chinese University of Hong Kong
Completed - verified April 2017

Study to Develop a Non-invasive Marker for Monitoring Myocardial Fibrosis

Conditions:   Hypertrophic Cardiomyopathy;   Acute Coronary Syndrome
Intervention:   Radiation: 99mTc-NC100692
Sponsor:   Ottawa Heart Institute Research Corporation
Active, not recruiting - verified April 2017

Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases

Conditions:   Occupational Accidents;   Incubation Period, Infectious Disese
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2, 2017

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

Conditions:   Severe Aplastic Anemia;   MDS (Myelodysplastic Syndrome)
Interventions:   Device: Miltenyi CD34 Reagent System;   Other: Donor derived G-CSF mobilized PBC
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 3, 2017

A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)

Conditions:   Myelodysplastic Syndromes;   Thrombocytopenia
Intervention:   Drug: Eltrombopag
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 30, 2017

High Cut-Off Continuous Veno-venous Hemodialysis (CVVHD) in Patients Treated for Acute Renal Failure After Systemic Inflammatory Response Syndrome (SIRS)/Septic Shock

Conditions:   Systemic Inflammatory Response Syndrome;   Kidney Failure, Acute
Intervention:   Device: continuous venovenous hemodialysis
Sponsors:   Baxter Healthcare Corporation;   Gambro Dialysatoren GmbH
Terminated - verified March 2017

Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelopdysplastic Syndrome

Conditions:   Myelodysplastic Syndrome (MDS);   Severe Aplastic Anemia (SAA)
Interventions:   Other: Umbilical Cord Blood;   Other: Haploidentical Stem Cells;   Device: Miltenvi CliniMACs CD34 Reagent System
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified December 6, 2016

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances

Conditions:   Immunosuppression;   Leukemia
Intervention:   Device: SOLEX 300i Stem Cell Selection
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified November 21, 2016

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Conditions:   Lymphoma;   Leukemia;   Myeloproliferative Disorders;   Multiple Myleoma;   Myelodysplastic Syndrome
Interventions:   Drug: Rituximab;   Drug: Fludarabine;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Procedure: PBSC transplantation;   Genetic: T cell DLI with sirolimus generated donor TH-2 cells;   Drug: Prednisone;   Procedure: Allogeneic HSCT;   Drug: Filgrastim;   Genetic: T-Rapa cell DLI
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified February 3, 2017

Surveillance of Streptococcal Infections in Children in India

Condition:   Group A Beta Hemolytic Streptococcal (GAS) Infection
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed - verified February 26, 2014

Experimental Bone Marrow Transplant Protocol

Conditions:   Acute Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Acute Myelocytic Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Disorders
Intervention:   Device: Isolex 300i Stem Cell Selection
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified July 14, 2016

Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy

Conditions:   Membranous Glomerulonephritis;   Lupus Membranous Nepropathy
Intervention:   Drug: Sirolimus
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified July 7, 2015

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

Conditions:   Mycosis Fungoides;   Sezary Syndrome
Intervention:   Drug: Campath-1H
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting - verified March 31, 2017

Eligibility Screening for a NCI Pediatric Oncology Branch Research Study

Conditions:   Ewing Sarcoma;   Osteosarcoma;   Neuroblastoma;   Acute Lymphoblastic Leukemia;   Neurofibromatosis Type 1
Sponsor:   National Cancer Institute (NCI)
Enrolling by invitation - verified March 7, 2017

Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension

Conditions:   Sickle Cell Anemia;   Pulmonary Hypertension
Interventions:   Drug: Nitric Oxide;   Device: INO Pulse - NO Delivery System
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Mallinckrodt
Completed - verified November 9, 2015

Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies

Conditions:   Hodgkin Lymphoma;   Lymphocytic Leukemia;   Mixed Cell Leukemia;   Myelodysplastic Syndrome;   Non Hodgkin's Lymphoma;   CML;   ALL;   AML;   Lymphoma
Intervention:   Procedure: Stem cell transplantation
Sponsor:   National Cancer Institute (NCI)
Completed - verified May 7, 2015

Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors

Conditions:   Wilms' Tumor;   Sarcoma;   Adenaocortical Carcinoma;   Refractory Cancer;   Coldrhood Cancer
Intervention:   Drug: Tariquidar
Sponsor:   National Cancer Institute (NCI)
Completed - verified January 13, 2016

Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults

Conditions:   Chronic Lymphocytic Leukemia;   Graft vs Host Disease;   Leukemia;   Myelodysplastic Syndrome;   Myeloid Leukemia
Intervention:   Procedure: Blood cell transplantation
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified December 28, 2016

The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers

Conditions:   Chronic Lymphocytic Leukemia;   Graft vs Host Disease;   Hematologic Neoplasm;   Multiple Myeloma;   Myelodysplastic Syndrome
Intervention:   Device: Isolex 300i plus MoAbs
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified July 8, 2016

Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow

Conditions:   Hematologic Disease;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome;   Myeloproliferative Disorder
Intervention:   Procedure: Stem cell transplantation
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 10, 2016

Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia

Conditions:   Graft vs Host Disease;   Hematologic Neoplasm;   Leukemia;   Multiple Myeloma;   Myelodysplastic Syndrome
Intervention:   Procedure: Allogeneic Bone Marrow Transplant
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified August 18, 2016